We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
DxGen

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App





Roche Acquires Stratos Genomics to Advance Development of DNA-Based Sequencing for Diagnostic Use

By LabMedica International staff writers
Posted on 23 May 2020
Print article
Image: SBX™ Genome Sequencing Technology (Photo courtesy of Stratos Genomics)
Image: SBX™ Genome Sequencing Technology (Photo courtesy of Stratos Genomics)
Roche (Basel, Switzerland) has acquired Stratos Genomics (Seattle, WA, USA), an early-stage sequencing technology company to advance the development of Roche’s nanopore sequencer.

The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion (SBX). The Roche nanopore sequencer, once developed, will utilize a novel approach that combines electronic and biological components to sequence DNA for fast, flexible and cost-effective clinical diagnostic testing. The addition of the SBX chemistry, once fully developed, is expected to provide the healthcare community an affordable, fast and flexible result, for multiple targeted clinical applications as well as whole exome and whole genome sequencing.

“Roche is dedicated to creating innovative diagnostics for the most challenging clinical conditions with techniques that are tailored to individual genetic and disease profiles. These solutions address the demands of research and clinical practice to deliver on the promise of personalised healthcare for patients,” said Thomas Schinecker, CEO Roche Diagnostics. “We look forward to further advancing our sequencing technology as we move to the next generation of healthcare and welcome the world-class scientists and employees from Stratos Genomics to Roche.”

“We are thrilled to join the Roche family, which will allow us to combine our unique Sequencing by Expansion chemistry with the Roche nanopore sequencer,” said Mark Kokoris, President & CEO at Stratos Genomics. “With our combined expertise and complementary technologies, we are well-positioned to open the path to deliver scalable, high-performance sequencing to clinicians and researchers.”




Print article

Channels

Molecular Diagnostics

view channel
Image: Schematic representation of Chiari malformation type 1; it involves the lower part of the cerebellum known as tonsils, but not the brain stem (Photo courtesy of Healthline).

Common Brain Malformation Traced to Its Genetic Roots

About one in 100 children has a common brain disorder called Chiari 1 malformation, but most of the time such children grow up normally and no one suspects a problem. However about one in 10 of those children,... Read more

Industry

view channel
Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.